ACC.25 – Diego Sadler reviews the results from the API-CAT study, which examined the efficacy and safety of low-dose apixaban versus full dose in patients with cancer-associated VTE. According to Sadler, it is good news for this patient population that the lower dose does not appear to be less effective and has a good safety signal.
Low-dose apixaban noninferior to full dose in cancer-associated VTE
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA.
Faculty
Diego Sadler, MD is section head Cardio-Oncology at the department of Cardiovascular Medicine AT Cleveland Clinic Florida in Weston, FL, USA. He is chair-elect of the ACC Cardio-Oncology Council.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 April 2025
The findings of this study were simultaneously published in N Engl J Med.
The information and data provided in this program were updated and correct at the time of its development, but may be subject to change.
Recommended
Details
Presenters
Overview
ACC.25 – Diego Sadler reviews the results from the API-CAT study, which examined the efficacy and safety of low-dose apixaban versus full dose in patients with cancer-associated VTE. According to Sadler, it is good news for this patient population that the lower dose does not appear to be less effective and has a good safety signal.
Educational information
This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA.
Faculty
Diego Sadler, MD is section head Cardio-Oncology at the department of Cardiovascular Medicine AT Cleveland Clinic Florida in Weston, FL, USA. He is chair-elect of the ACC Cardio-Oncology Council.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 April 2025
The findings of this study were simultaneously published in N Engl J Med.
The information and data provided in this program were updated and correct at the time of its development, but may be subject to change.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
<p>Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy</p>
CME/CE
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
1.00 credits
<p>Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
MinuteCE®
Clinical Conundrums in ARIA: How to Manage Asymptomatic ARIA
1.25 credits
<p>Clinical Conundrums in ARIA: How to Manage Asymptomatic ARIA</p>
CME/CE Broadcast Replay
Pulmonary Hypertension Management: Practice Trends and Updates
1.00 credits
<p>Pulmonary Hypertension Management: Practice Trends and Updates</p>
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 credits
<p><span data-contrast="auto" style="list-style-type: disc;" xml:lang="EN-US">Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies</span></p>
NeuroFrontiers
Respiratory Dysfunction in Neuromuscular Disorders: Evaluating Symptoms
<p>Respiratory Dysfunction in Neuromuscular Disorders: Evaluating Symptoms</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?